Trikafta for 6-11 going back to the PBAC

Disappointingly Trikafta for 6-11s is going back to the PBAC as an agreement has not been reached. It will be discussed this week with the outcome released on April 21.

This is not good enough Mark Butler MPVertex Pharmaceuticals. Heading back to the standard PBAC process leads to further uncertainty with the approval and timeframe, with July or Aug as the potential minimum listing date.

Please fast track this process as the more time we wait, the more time we lose. Thirty other countries have prioritised the lives of the young ones with CF, please don’t continue to leave Australians behind.


Anthony AlbaneseSenator Anne Ruston